NYSE:LLYPharmaceuticals
Eli Lilly Expands Korea Gateway Labs As Valuation Signals Potential Upside
Eli Lilly (NYSE:LLY) has partnered with Samsung Biologics to establish a new Lilly Gateway Labs site in Korea.
This marks the first international expansion of Lilly's Gateway Labs model, which supports early stage biotech companies.
The Korea site is intended to attract biotech startups and deepen Lilly's presence in Asian life sciences ecosystems.
Eli Lilly enters this move with a share price of $1,001.35 and a multi year return that is very large over the past 5 years. Over the last year,...